Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab added to medium to high-dose ICS-LABA in patients with uncontrolled asthma
2017-000702-38Phase 3
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Benralizumab arm with Placebo arm (2 arms). Primary endpoint: Annual asthma exacerbation rate.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-000702-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000702-38.